Trial Profile
Phase I/II Trial of Vorinostat and Radiation Therapy in Patients With Locally Advanced Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 05 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 May 2010 New source identified and integrated (M.D. Anderson Cancer Center, 2008-0780).
- 14 May 2009 Actual initiation date (May 2009) added as reported by ClinicalTrials.gov.